Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Senior VP, CDO | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2036-01-01 | Direct | 18,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 20:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000696 · ownership.xml · derivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 18:57 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000413 · section16.xml · derivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 21:01 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy · Derivative | 50,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000295 · section16.xml · derivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:06 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001654954-23-000146 · section16.xml · derivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, CDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 20:04 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001654954-22-009392 · section16.xml · derivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, CDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-30 F1 · derivative.exercise_date: The option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:22 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000905718-22-000052 · dermata_fm4jan32022.xml · derivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:39 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1 Preferred Stock · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001096 · dermata_fm4aug172021.xml · derivative · entry 3 Nardo Christopher J. · CIK 0001870247 · Senior VP, Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Nardo Family Trust Dated October 3, 2001 Disclosed balance after: 0 Underlying: Common Stock · 2,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1 Preferred Stock was convertible at any time and had no expiration date. F1 · derivative.exercise_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1 Preferred Stock was convertible at any time and had no expiration date. F1 · derivative.expiration_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1 Preferred Stock was convertible at any time and had no expiration date. F2 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:39 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 2,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001096 · dermata_fm4aug172021.xml · nonDerivative · entry 1 Nardo Christopher J. · CIK 0001870247 · Senior VP, Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Nardo Family Trust Dated October 3, 2001 Disclosed balance after: 2,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1 Preferred Stock was convertible at any time and had no expiration date. F2 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.